Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI: A Subgroup Analysis of the BIOSTEMI Randomized Trial

JACC Cardiovasc Interv. 2020 Oct 12;13(19):2314-2316. doi: 10.1016/j.jcin.2020.07.038.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorbable Implants
  • Coronary Artery Disease* / therapy
  • Drug-Eluting Stents*
  • Everolimus
  • Humans
  • Percutaneous Coronary Intervention*
  • Prosthesis Design
  • Sirolimus
  • Treatment Outcome

Substances

  • Everolimus
  • Sirolimus